Discontinuing Teclistamab Early Yields Comparable Efficacy vs Continuous Therapy in RRMM
The 6- and 12-month PFS rates were 76.4% and 68.2%, respectively, in patients with relapsed/refractory multiple myeloma who discontinued treatment with teclistamab early.
Why Sexual and Gender Minority Care is an Oncologic Imperative
Daniel C. McFarland, DO, and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.
Axatilimab Confers Promising Early Efficacy/Tolerability in Chronic GVHD
Across all dose levels of axatilimab, the 46-month OS rate was the 74.1% among patients with previously treated chronic graft-vs-host disease.
How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025
Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.
Resecting MRI-Detected Disease Doesn’t Improve Outcomes in Early-Stage BC
The 60-month local regional recurrence-free rate was 93.2% in the MRI arm vs 95.7% in the no MRI arm among patients with newly diagnosed breast cancer.
Pembrolizumab/Radiation Improves T Cell Infiltration in Early Breast Cancer
Findings from the P-RAD trial show encouraging rates of pathologic complete response among patients who received pembrolizumab plus radiotherapy.
